•
Jun 30, 2022
Onconova Q2 2022 Earnings Report
Announced financial results for the second quarter of 2022 and provided a business update.
Key Takeaways
Onconova Therapeutics reported a net loss of $4.0 million for the second quarter of 2022, with cash and cash equivalents totaling $46.5 million as of June 30, 2022. The company believes its cash will be sufficient to fund operations for at least eighteen months.
Narazaciclib continues to show a favorable safety profile in Phase 1 studies.
A Phase 2 trial evaluating rigosertib combined with a PD-1 checkpoint inhibitor in checkpoint inhibitor refractory metastatic melanoma is on schedule to open for enrollment in the second half of 2022.
Data provided strong evidence of rigosertib doublet’s activity in patients who previously failed checkpoint inhibitor therapy
Responses seen with rigosertib are agnostic to the type of KRAS mutation present.